Crystagen is a research-only peptide bioregulator with no regulator-approved dosing framework. The amounts below are anecdotal, not standardized, and not medically established. They are shown for education, not as a protocol. Amounts vary widely between sources. Any use should start low and be supervised by a qualified clinician.
Overview
Crystagen is a short peptide from the Khavinson "bioregulator" family, whose proponents describe it as acting at very low signalling levels rather than through classical dose-response pharmacology. Because there is no approved label, there is no authoritative dose — only anecdotal community usage.
Common dosing pattern
Bioregulators in this family are generally described as used in short cycles rather than continuously:
- Commonly cited amounts are small — on the order of ~10 mg per day — but reported figures vary and are not standardized.
- Typically run in short courses of roughly 10–20 days, sometimes repeated a few times per year.
- Injectable and oral (capsule) presentations are both marketed, and reported amounts differ between them.
These are anecdotal figures with thin supporting evidence. There is no established therapeutic range.
How it is administered
Injectable Crystagen ships as a lyophilized powder reconstituted with bacteriostatic water, then given subcutaneously or intramuscularly; oral versions are taken as capsules.
- For injectables, the final dose depends on reconstitution — water volume sets concentration, read as syringe units.
- As unregulated products, actual peptide content and purity are not verified.
Why oversight matters
Crystagen has no defined indications, contraindications, or monitoring standards, and the low-dose "bioregulator" mechanism remains a hypothesis rather than validated pharmacology. A clinician can weigh individual health context that vial math cannot. Treat the pattern above as background, not instruction.